Form 4: Nuvalent Executive Darlene Noci Executes Stock Option and Sells Shares Under 10b5-1 Plan

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Darlene Noci, Chief Development Officer of Nuvalent, Inc., executed a transaction involving the company's Class A Common Stock on April 29, 2025.
• Noci exercised stock options to acquire 4,000 shares at a price of $14.40 per share.
• Simultaneously, Noci sold 4,000 shares at a weighted average price of $74.56, with individual sales ranging from $74.23 to $75.13.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024.
• Following these transactions, Noci directly owns 48,034 shares of Class A Common Stock and holds options for 23,388 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company executives. It is common for executives to utilize 10b5-1 trading plans to manage their stock holdings and avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The use of Rule 10b5-1 trading plans is a common strategy among corporate insiders to manage their stock transactions in compliance with securities laws.
• Comparable companies in the biotechnology sector, such as Relay Therapeutics or Black Diamond Therapeutics, also have executives who regularly file Form 4s related to stock option exercises and sales.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of shares available in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Nuvalent, NUVL, Darlene Noci, Chief Development Officer, Stock Options, Class A Common Stock, Form 4, Rule 10b5-1, Insider Trading, SEC